Cardiovascular · Oral PCSK9 inhibitor (once-daily tablet)

Enlicitide (Lipfendra)

Enlicitide (Lipfendra) is the first oral PCSK9 inhibitor, approved by the FDA in July 2026 to lower LDL cholesterol. It cut LDL by about 56% to 59% versus placebo in Phase 3. Whether it reduces heart attacks and strokes is being tested in a 14,550-participant outcomes trial.

FDA-approvedFDA-approved July 2026 as the first oral PCSK9 inhibitor; cardiovascular outcomes trial ongoing

FDA-approved: Approved by the FDA for at least one use. Other uses may still be in clinical trials. About status badges

FDA: approved as LIPFENDRA (NDA220848), original approval Jul 15, 2026. Approval covers specific uses only; see programs below.

DeveloperMerck & Co. (MSD) · Merck & Co. pipeline
Drug typeOral PCSK9 inhibitor (once-daily tablet)
TargetProprotein convertase subtilisin/kexin type 9 (PCSK9)
MechanismInhibits PCSK9, allowing the liver to keep more LDL receptors and clear more LDL cholesterol from the blood
Other namesMK-0616, enlicitide decanoate

Key points

  • Enlicitide blocks PCSK9, the same target as injectable evolocumab and alirocumab, but as a once-daily pill.
  • The FDA approved it as Lipfendra in July 2026 for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise.
  • In the 2,909-participant CORALreef Lipids trial, LDL cholesterol fell 57.1% at week 24, compared with a 3.0% rise with placebo, in patients already on statins.
  • The approval is based on LDL lowering. The FDA's announcement did not claim a reduction in heart attacks or strokes, which is being tested in CORALreef Outcomes (estimated 14,550 participants).
  • It received Priority Review and was reviewed under the FDA Commissioner's National Priority Voucher pilot.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Hypercholesterolemia and atherosclerotic cardiovascular disease
Approved to reduce LDL cholesterol (FDA). A cardiovascular outcomes trial, needed for an event-reduction claim, is active, not recruiting (registry).
Approved (FDA, July 2026) for LDL lowering; outcomes trial ongoing12
4 active · 8 completed
Not shown (see note)

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What enlicitide is

Enlicitide is an oral PCSK9 inhibitor developed by Merck & Co. (known as MSD outside the U.S. and Canada). PCSK9 is a protein that causes the liver to destroy its LDL receptors, the receptors that pull LDL cholesterol out of the blood. Blocking PCSK9 leaves more receptors in place, so LDL levels fall. Until enlicitide, every approved PCSK9-targeting drug was an injection.

A target found through human genetics

PCSK9 is one of the clearest examples of a drug target discovered through genetics. In 2006, researchers reported that people carrying natural variants that disable PCSK9 had lifelong lower LDL cholesterol and substantially lower rates of coronary heart disease. Among Black participants, these variants were associated with 28% lower LDL and an 88% lower risk of coronary heart disease. That finding led directly to the injectable PCSK9 antibodies, and now to an oral drug. See What Are Genetic Mutations?

Regulatory status

The FDA approved Lipfendra (enlicitide), NDA 220848, on July 15, 2026, and announced it on July 17. According to the FDA, it is approved as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). It received Priority Review and was reviewed under the Commissioner's National Priority Voucher pilot program. The label specifies a 20 mg tablet taken once daily on an empty stomach in the morning.

The approval is based on LDL lowering. The FDA's announcement does not claim that enlicitide reduces heart attacks or strokes.

Clinical evidence

CORALreef Lipids

This trial enrolled adults with a history of a major atherosclerotic cardiovascular event, or at risk of a first event, who were already receiving statins. Published in the New England Journal of Medicine in 2026:

Measure Enlicitide Placebo
Participants (intention-to-treat) 1,935 969
Mean baseline LDL cholesterol 96.1 mg/dL (all participants)
Change in LDL cholesterol at week 24 −57.1% +3.0%
Between-group difference −55.8 percentage points

Non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) also fell significantly more with enlicitide. The incidence of adverse events did not appear to differ between the groups.

CORALreef HeFH

In 303 adults with heterozygous familial hypercholesterolemia, a mean baseline LDL of 119 mg/dL, and all taking statins, LDL fell 58.2% with enlicitide at week 24, compared with a 2.6% rise with placebo. The between-group difference was −59.4 points at week 24 and −61.5 points at week 52 (JAMA, 2026).

CORALreef Outcomes

This is the trial that will determine whether enlicitide reduces cardiovascular events. ClinicalTrials.gov lists an estimated 14,550 participants and an estimated primary completion in November 2029.

Scientific perspective

LDL cholesterol is a validated surrogate endpoint. The Lipfendra label makes the reasoning explicit: it notes that cardiovascular outcomes trials have shown that reducing LDL lowers the risk of major adverse cardiovascular events in adults treated with statins or with monoclonal antibody PCSK9 inhibitors added to statins. In other words, the approval relies on outcomes evidence from other LDL-lowering drugs, including drugs acting on the same target. Surrogates have misled before, however (see What Is a Primary Clinical Trial Endpoint?), so the outcomes trial still matters for confirming the benefit and assessing long-term safety.

Development perspective

  • Approved use: LDL lowering in adults with hypercholesterolemia, including HeFH. No benchmark is shown because the program is approved.
  • Next milestone: CORALreef Outcomes, estimated primary completion November 2029 (registry). A positive result could support a cardiovascular risk-reduction claim.
  • Further programs: pediatric familial hypercholesterolemia (Phase 2/3, recruiting) and a Phase 2 combination study with another Merck investigational drug, MK-7262 (registry).

Competitive context

Enlicitide joins statins, ezetimibe, bempedoic acid, injectable PCSK9 antibodies, and the PCSK9 siRNA inclisiran. It is the first PCSK9-targeting option in pill form. A once-daily oral PCSK9 inhibitor competes on convenience, while the injectables offer dosing every two weeks to every six months. Oral CETP inhibition with obicetrapib, which is approved in the EU but not the U.S., is another oral LDL-lowering approach in development.

Development timeline

  1. Mar 10, 2022Phase 2 trial of MK-0616 begins (381 participants). Registry
  2. Aug 10, 2023CORALreef Lipids Phase 3 trial begins. Registry
  3. Oct 9, 2023CORALreef Outcomes cardiovascular outcomes trial begins. Registry
  4. Jan 13, 2026CORALreef HeFH published: LDL −58.2% versus +2.6% with placebo at week 24 in heterozygous familial hypercholesterolemia. Peer-reviewed
  5. Feb 5, 2026CORALreef Lipids published: LDL −57.1% versus +3.0% with placebo at week 24. Peer-reviewed
  6. Jul 15, 2026FDA approves Lipfendra (enlicitide), NDA 220848, the first oral PCSK9 inhibitor. Regulator

What could change the outlook

  • The CORALreef Outcomes result, which will show whether enlicitide reduces major cardiovascular events. The registry estimates primary completion in November 2029.
  • Real-world adherence, since the pill is taken once daily on an empty stomach in the morning, according to the label.
  • Regulatory decisions outside the U.S.
  • Pediatric results from the Phase 2/3 trial in children with familial hypercholesterolemia (registry).

Latest company disclosures

Company press releases (SEC filings and PR Newswire) that mention Enlicitide. Company-reported, not independently verified.

  1. Quarterly reportCompany-reportedAug 4, 2026

    Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

    “The FDA approval of LIPFENDRA is an exciting moment for our company and for patients, marking the latest milestone in our nearly 70-year legacy in cardiovascular disease.

    Source
    SEC Form 8-K · Financial results

All Enlicitide disclosures in Pipeline News

Clinical trials

34 registered trials list Enlicitide as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Hypercholesterolemia and atherosclerotic cardiovascular disease

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06008756
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
Phase 3Active, not recruiting14,550 (est.)Nov 29, 2029 (est.)No
NCT06492291
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
Phase 3Active, not recruiting3,000 (est.)Oct 13, 2028 (est.)No
NCT05952856
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
Phase 3Completed2,912Jul 28, 2025Yes
NCT07216482
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Phase 3Completed996Aug 3, 2026No
NCT05952869
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
Phase 3Completed303Apr 7, 2025Yes
NCT06450366
A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
Phase 3Completed301Feb 14, 2025Yes
NCT07058077
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Phase 2/3Recruiting153 (est.)Dec 4, 2033 (est.)No
NCT07821944
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)
Phase 3Recruiting150 (est.)Nov 26, 2027 (est.)No
NCT05261126
A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
Phase 2Completed381Nov 28, 2022Yes
3 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06655311
A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)
Phase 1Completed56Jan 2, 2024No
NCT05934292
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)
Phase 1Completed33Jan 19, 2024Yes
NCT06592339
A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)
Phase 1Completed24Dec 29, 2022No

Clinical pharmacology and supporting studies

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07614984
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Phase 2Recruiting750 (est.)Oct 12, 2027 (est.)No
21 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07044479
A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)
Phase 1Completed60Aug 13, 2025No
NCT07300280
A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)
Phase 1Completed60Oct 14, 2026No
NCT06691906
A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)
Phase 1Completed40May 1, 2024No
NCT06880874
A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)
Phase 1Completed40May 16, 2025No
NCT06699329
A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
Phase 1Completed38May 24, 2024No
NCT06814106
A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)
Phase 1Completed37May 8, 2023No
NCT06772779
A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)
Phase 1Completed36Jun 4, 2024No
NCT06772792
A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)
Phase 1Completed36Jun 21, 2024No
NCT06658652
The Effect of Food and Water Volume in Healthy Adult Participants Administered Enlicitide Decanoate (MK-0616) (MK-0616-022)
Phase 1Completed34Dec 26, 2023No
NCT07481708
A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)
Phase 1Completed30May 18, 2026No
NCT07619443
A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)
Phase 1Completed30Sep 5, 2026No
NCT07776665
A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)
Phase 1Active, not recruiting30 (est.)Dec 14, 2026 (est.)No
NCT06625814
A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)
Phase 1Completed28Aug 19, 2024No
NCT06643377
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
Phase 1Completed27Jun 25, 2025Yes
NCT06597760
A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
Phase 1Completed24Nov 1, 2024No
NCT06575959
A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)
Phase 1Completed20May 1, 2025Yes
NCT06609512
A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)
Phase 1Completed20Jan 13, 2025No
NCT05070390
A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)
Phase 1Completed18May 3, 2023Yes
NCT06699355
A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)
Phase 1Completed18Dec 29, 2023No
NCT06719544
A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034)
Phase 1Completed16Jan 27, 2025No
NCT06658626
A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)
Phase 1Completed8Aug 2, 2023No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. U.S. Food and Drug Administration. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol (July 17, 2026).Regulator
  2. Navar AM, et al. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide (CORALreef Lipids). New England Journal of Medicine. 2026;394(6):529–539.Peer-reviewed
  3. Ballantyne CM, et al. Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia (CORALreef HeFH). JAMA. 2026;335(2):129–139.Peer-reviewed
  4. U.S. Food and Drug Administration. Lipfendra (enlicitide) prescribing information, NDA 220848.Regulator
  5. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine. 2006;354(12):1264–1272.Peer-reviewed
  6. ClinicalTrials.gov. CORALreef Outcomes (NCT06008756).Registry
  7. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.